Clinical Trials - August 13, 2015
Findings from the QUALIFY study
Otsuka Pharmaceutical and Lundbeck has announced that a newly released subgroup analysis of data from the QUALIFY study showed significantly greater and clinically meaningful improvements in functioning and health-related quality of life with aripiprazole once-monthly compared with paliperidone palmitate in patients aged 18-35 years living with schizophrenia 1. “These latest findings from the QUALIFY study […]
Drug Development Pharma - March 20, 2014
Lundbeck and Otsuka initiate European launch of Abilify Maintena
The two companies has announced the launch of Abilify Maintena in Europe following approval by the European Commission in November 2013. Denmark is the first European country where Abilify Maintena is fully reimbursed and accessible to people with schizophrenia, and more than ten markets are expected to launch by the end of 2014. Abilify Maintena (aripiprazole) is […]
Collaboration - December 11, 2013
Lundbeck and Otsuka to develop investigational vaccine candidate
H. Lundbeck and Otsuka Pharmaceutical today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer’s disease. Lu AF20513 is an anti-Aβ active vaccine candidate for Alzheimer’s disease which currently is in preclinical development. It is designed towards an optimal immunogenic response in the elderly, […]
Drug Development Pharma - September 25, 2013
Otsuka and Lundbeck receive positive CHMP opinion for Abilify Maintena(r) in schizophrenia
Lundbeck and Otsuka today announced a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization for Abilify Maintena (aripiprazole), an intramuscular (IM) depot formulation for the maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole. “Abilify Maintena has been available in the US for […]
